GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atrion Corp (NAS:ATRI) » Definitions » 10-Year RORE %

Atrion (Atrion) 10-Year RORE % : -2.74% (As of Dec. 2023)


View and export this data going back to 1972. Start your Free Trial

What is Atrion 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Atrion's 10-Year RORE % for the quarter that ended in Dec. 2023 was -2.74%.

The industry rank for Atrion's 10-Year RORE % or its related term are showing as below:

ATRI's 10-Year RORE % is ranked worse than
59.9% of 394 companies
in the Medical Devices & Instruments industry
Industry Median: 2.48 vs ATRI: -2.74

Atrion 10-Year RORE % Historical Data

The historical data trend for Atrion's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atrion 10-Year RORE % Chart

Atrion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.01 3.86 4.91 5.28 -2.74

Atrion Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.28 2.81 1.35 -1.58 -2.74

Competitive Comparison of Atrion's 10-Year RORE %

For the Medical Instruments & Supplies subindustry, Atrion's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrion's 10-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Atrion's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Atrion's 10-Year RORE % falls into.



Atrion 10-Year RORE % Calculation

Atrion's 10-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 11.02-14.09 )/( 168.49-56.28 )
=-3.07/112.21
=-2.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 10-year before.


Atrion  (NAS:ATRI) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Atrion 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Atrion's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atrion (Atrion) Business Description

Traded in Other Exchanges
N/A
Address
One Allentown Parkway, Allen, TX, USA, 75002-4211
Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.
Executives
Preston G Athey director ONE ALLENTOWN PKWY, ALLEN TX 75002
David A Battat officer: President & CEO 2700 HALKEY-ROBERTS PLACE NORTH, ST. PETERSBURG FL 33716-4103
Jeannette Bankes director ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Morgan Hugh J Jr director
Ronald Nicholas Spaulding director ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Cindy Ferguson officer: Officer/ CFO ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffery Strickland officer: Vice President & CFO
Emile A Battat director, officer: Chairman ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Stupp John P Jr director STUPP JOHN P JR, #18 ST. ANDREWS DR., ST LOUIS MO 63124
Roger F Stebbing director
Ronald N Spaulding director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Richard O Jacobson director ONE ALLENTOWN PARKWAY, C/O ATRION, ALLEN TX 75002
Maley John H P director 6 ROCK CREST LANE, SIGNAL MOUNTAIN TN 37377
Margaret Maxwell Zagel director C/O TELLABS OPERATIONS INC, 4951 INDIANA AVE, LISLE IL 60532

Atrion (Atrion) Headlines

From GuruFocus

Atrion Reports Second Quarter 2022 Results

By PurpleRose PurpleRose 08-08-2022

Atrion Corporation Announces CFO Succession Plan

By GlobeNewswire GlobeNewswire 08-25-2022

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 06-23-2022

Atrion Reports First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 06-08-2022

Atrion Corporation Declares Quarterly Cash Dividend

By Don Li2 Don Li2 11-12-2021

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 06-03-2022

Atrion Corporation Declares Quarterly Cash Dividend

By PurpleRose PurpleRose 07-14-2022

Atrion Reports Third Quarter 2022 Results

By Value_Insider Value_Insider 11-08-2022

Atrion Corporation Declares Quarterly Cash Dividend

By sperokesalga sperokesalga 05-23-2023

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 06-13-2022